Evotec stock gains modestly as investors weigh recent setbacks

Evotec stock (ISIN DE0005664809) closed at EUR 2.91 on Xetra on September 18, 2026, up 1.1 percent on the day and only slightly above its 52-week low, signaling a fragile recovery for the Hamburg-based biotech group.

Price hovers near 52-week low

According to Investing.com data as of September 18, 2026, Evotec shares traded on Xetra under the ticker EVTG at EUR 2.914, with an intraday range between EUR 2.912 and EUR 3.098 and a daily gain of 1.1 percent compared with the prior close of EUR 2.914.

Over the last 52 weeks, the stock has moved between a low of EUR 2.766 and a high of EUR 7.300, meaning the September 18, 2026 closing level of EUR 2.914 is only about 5.4 percent above the low and roughly 60.1 percent below the high, underscoring how deeply the share price has corrected from earlier levels.

Market capitalization reflects compressed valuation

Evotec’s market capitalization stood at around EUR 512.3 million as of September 18, 2026, based on the Xetra closing price and figures reported by Investing.com, highlighting how far the valuation has fallen for a company that was previously valued in the multi-billion-euro range.

For investors, the combination of a sub-EUR 3 share price and a market cap just above EUR 500 million puts renewed focus on whether the company can stabilize its operating performance and rebuild confidence in its drug discovery and development partnerships.

Recent analysis points to elevated risk

A detailed investor update published on September 19, 2026 by the Wolf of Value investing group on Seeking Alpha takes a markedly cautious view of Evotec’s prospects, emphasizing what it describes as heightened risk factors and a reduced appeal even as a speculative investment.

In this update, the author explains that while they are maintaining their existing position to retain exposure to a potential recovery, they would not currently add to the stock and characterize Evotec as better avoided for new money given the operational and execution risks identified in recent quarters.

Stock remains under pressure despite small rebound

From an investor perspective, the key takeaway is that Evotec stock remains deeply depressed relative to its 52-week high, with the modest 1.1 percent gain on September 18, 2026 offering only a small respite in a longer downtrend driven by skepticism over the company’s ability to deliver on its pipeline and partnership model.

At the same time, the roughly EUR 512.3 million market capitalization suggests that expectations embedded in the share price are now very low, which could provide upside if Evotec can present clearer evidence of improving fundamentals, but the recent cautious analysis reinforces that this turnaround is far from assured.

Share price and investor view

As of the Xetra close on September 18, 2026, Evotec stock traded at EUR 2.91, leaving the shares near their 52-week low and reflecting an investor base that is still waiting for convincing operational progress before re-rating the company.

More news and analyses on Evotec stock